Acute lymphoblastic leukemia (ALL) treatment is evolving at a rapid pace, and many HCPs may see only a few patients with B-cell
precursor ALL per year. The goal of the CatALLyst™ initiative created by Amgen Oncology is to inform HCPs about the latest
considerations for treating ALL, starting with MRD.
ALL, acute lymphoblastic leukemia; CR, complete remission; HCP, healthcare professional; MRD, measurable residual disease.
Reference: Samra B, Jabbour E, Ravandi F, et al. Evolving therapy of adult
acute lymphoblastic leukemia: state-of-the-art treatment and future directions.
J Hematol Oncol. 2020;13:70.